COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W5WZ
|
|||
| Drug Name |
Tideglusib
|
|||
| Synonyms |
NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
| Other Indication | Alzheimer disease | Phase 2 | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H14N2O2S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43
|
|||
| InChI |
1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
|
|||
| InChIKey |
PMJIHLSCWIDGMD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 865854-05-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:147398
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [1] |
| Tideglusib inhibits SARS-CoV-2 Mpro through a combination of structure-based screening and FRET-based enzymatic assay (IC50 = 1.82 microM). | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. | |||
| 2 | A Phase II Trial of Tideglusib in Alzheimer's Disease. J Alzheimers Dis. 2015;45(1):75-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.